Holger Zimmermann
Directeur Général chez AiCuris GmbH & Co. KG
Profil
Holger Zimmermann is currently the Chief Executive Officer at AiCuris Verwaltungs-GmbH.
He is also the Chief Executive Officer at AiCuris GmbH & Co. KG since 2015.
Additionally, he serves as the Co-Managing Director at G&Z Montageservice GmbH.
In his former positions, Dr. Zimmermann worked as the Director-Antiviral Research at Bayer AG from 2000 to 2006.
He also held the position of Principal at the National University of Singapore.
Postes actifs de Holger Zimmermann
| Sociétés | Poste | Début |
|---|---|---|
AiCuris GmbH & Co. KG
 AiCuris GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services AiCuris GmbH & Co. KG provides research and development services for antiviral and antibacterial agents. The firm develops drugs against viruses such as human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company was founded in March 2006 and is headquartered in Wuppertal, Germany. | Directeur Général | 01/03/2015 |
AiCuris Verwaltungs-GmbH
 AiCuris Verwaltungs-GmbH Miscellaneous Commercial ServicesCommercial Services AiCuris Verwaltungs GmbH engages in the acquisition and management of participating interests in firms, whose business activities focus on research and development as well as service provision in the healthcare sector. The company was founded on September 1, 2005 and is headquartered in Wuppertal, Germany. | Directeur Général | - |
G&Z Montageservice GmbH
 G&Z Montageservice GmbH Marine ShippingTransportation G & Z Montageservice GmbH is a German company that provides contract-based services for the deployment of assembly and service personnel. The private company is based in Castrop Rauxel, Germany. The company's goal is to execute projects around the world quickly, safely, and professionally. The company specializes in industrial assembly and strive to provide excellent service and project management. The CEOs of the company are Holger Zimmermann, Bernd Uttich. | Directeur Général | - |
Aicuris Anti-Infective Cures AG
 Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Directeur Technique/Scientifique/R&D | 01/04/2023 |
Anciens postes connus de Holger Zimmermann
| Sociétés | Poste | Fin |
|---|---|---|
| BAYER AG | Corporate Officer/Principal | 01/01/2006 |
| National University of Singapore | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BAYER AG | Health Technology |
| Entreprise privées | 4 |
|---|---|
AiCuris Verwaltungs-GmbH
AiCuris Verwaltungs-GmbH Miscellaneous Commercial ServicesCommercial Services AiCuris Verwaltungs GmbH engages in the acquisition and management of participating interests in firms, whose business activities focus on research and development as well as service provision in the healthcare sector. The company was founded on September 1, 2005 and is headquartered in Wuppertal, Germany. | Commercial Services |
AiCuris GmbH & Co. KG
AiCuris GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services AiCuris GmbH & Co. KG provides research and development services for antiviral and antibacterial agents. The firm develops drugs against viruses such as human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company was founded in March 2006 and is headquartered in Wuppertal, Germany. | Commercial Services |
G&Z Montageservice GmbH
G&Z Montageservice GmbH Marine ShippingTransportation G & Z Montageservice GmbH is a German company that provides contract-based services for the deployment of assembly and service personnel. The private company is based in Castrop Rauxel, Germany. The company's goal is to execute projects around the world quickly, safely, and professionally. The company specializes in industrial assembly and strive to provide excellent service and project management. The CEOs of the company are Holger Zimmermann, Bernd Uttich. | Transportation |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Commercial Services |
